Immuneering Gets Encouraging Data From Ongoing IMM-1-104 Trial For Pancreatic Cancer Treatment

(RTTNews) - Immuneering Corp. (IMRX), Tuesday announced positive data update from three arms of its ongoing Phase 2a trial of lead program IMM-1-104 for the treatment of patients with Pancreatic cancer.

Following the announcement, Immuneering's stock is surging 103.39 percent, to $4.83 on the Nasdaq.

The drug showed an overall response rate of 43 percent and disease control rate of 86 percent in first-line Pancreatic cancer patients, when combined with modified gemcitabine/nab-paclitaxel. Whereas, the combination with modified Folfirinox demonstrated target lesion shrinkage in all evaluable patients, including a 100 percent reduction.

Meanwhile, the initial data for IMM-1-104 monotherapy in second-line pancreatic cancer revealed a partial response of 67 percent target lesion reduction, demonstrated activity and supported development in first-line combinations.

The biotechnology company intends to add three new Phase 2a combination arms - IMM-1-104 with a BRAF inhibitor in BRAF-mutant melanoma, and IMM-1-104 with an immune checkpoint inhibitor in both melanoma and non-small cell lung cancer, set to begin in 2025.